KalVista Pharmaceuticals, Inc. Common Stock
Symbol: KALV (NASDAQ)
0.00
▼ (-100.00%) -11.540
Company Description:
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $11.54
- Yesterday High: $11.55
- Yesterday Low: $10.84
- Yesterday Volume: 1.23M
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: KalVista Pharmaceuticals, Inc. Common Stock
- Website: https://www.kalvista.com
- Listed Date: 2015-04-09
- Location: FRAMINGHAM, MA
- Market Status: Active
- CIK Number: 0001348911
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $583.04M
- Round Lot: 100
- Outstanding Shares: 50.52M
- Asset Type: CS
RECENT FILINGS FOR KALV
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-08 | 4 | View |
| 2025-10-08 | 3 | View |
| 2025-10-06 | 8-K | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 3 | View |
| 2025-10-02 | 8-K | View |
| 2025-09-29 | 8-K | View |
| 2025-09-11 | 10-Q | View |
| 2025-09-11 | 8-K | View |
| 2025-09-09 | 4 | View |
| 2025-08-26 | 4 | View |
| 2025-08-26 | 4 | View |
| 2025-08-26 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 3 | View |
Latest News on KALV